The inaugural feature, published 19th January, highlights the UK’s fastest-growing private companies developing or selling unique, proprietary technologies, and is backed by Singer Capital Markets, HSBC Innovation Banking and BDO.
The inaugural feature, published 19th January, highlights the UK’s fastest-growing private companies developing or selling unique, proprietary technologies, and is backed by Singer Capital Markets, HSBC Innovation Banking and BDO.
The future of drug discovery holds immense promise, and Metrion is well-positioned to make meaningful contributions to advancing human health. I look forward to embarking on this exciting journey with all of you.
As we celebrate this significant milestone, we take pride in the contributions of our entire team, whose expertise and dedication have been instrumental in shaping who we are today. We’re equally grateful to our customers and collaborators, whose trust and partnership have been pivotal to our success.
Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders'
An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.
With enthusiastic engagement from staff, we’ve cultivated a robust H&S culture, ensuring we continuously prioritize the health, safety, and well-being of everyone at Metrion.
IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.
IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.
'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics) receives ‘2024 Technology Innovation Publication Award’.
Metrion Biosciences provides GLP hERG testing services which crucial for drug discovery and the Investigational New Drug (IND) process. Our focus is on delivering reliable, regulatory-compliant data quickly and cost-effectively.